MedPharm Appoints Bill Humphries as Chief Executive Officer to Lead Next Phase of Strategic Growth

DURHAM, N.C., Feb. 4, 2025 /PRNewswire/ -- MedPharm, a global leader in topical and transdermal contract drug development and manufacturing, today announced the appointment of Bill Humphries as Chief Executive Officer. Bill's leadership will enable MedPharm to accelerate its strategic growth following its merger with Tergus Pharma which significantly bolstered MedPharm's scientific, clinical trial manufacturing, and commercial production capabilities.

As CEO of MedPharm, Mr. Humphries brings over 36 years of leadership and business transformation experience in the pharmaceutical and life sciences industries. Most recently he was CEO of Alcami where he spearheaded operational improvements, revenue growth, and client satisfaction. Prior to Alcami, he served as CEO at Isosceles Pharmaceuticals, President and Group Company Chairman of Ortho-Dermatologics, CEO of Merz North America, President of Stiefel, a GSK Company and Vice President of US Skincare at Allergan Pharmaceuticals. He has served as Chairman of the Board at Clearside Biomedical, Executive Chairman of Strata Skin Sciences, and a member of the Board of Directors at Alcami, Aclaris Therapeutics, PhaseBio Pharmaceuticals, SKNV, and Bryn Pharmaceuticals. Mr. Humphries holds a B.A. from Bucknell University and MBA from Pepperdine University.

"It is a privilege to join MedPharm and the team at this important period in MedPharm's evolution and growth aspirations," said Bill Humphries, Chief Executive Officer of MedPharm. "I am excited to be part of this team and leverage my direct experience in the topical and transdermal space to accelerate MedPharm's growth. I believe MedPharm is well positioned to serve clients across all channels in the topical space and we look forward to delivering incremental value for trusted existing and new clients."

Pat Walsh, Chairman of the Board added, "Bill's extensive leadership experience and deep understanding of the pharmaceutical industry make him the ideal leader to guide MedPharm through its next phase of growth. With his expertise and the strength of our combined organization, MedPharm is well-positioned to set new standards in topical and transdermal CDMO services."

MedPharm's investors include Ampersand Capital Partners, Bourne Partners Strategic Capital and Great Point Partners.

About MedPharm
MedPharm is an end-to-end contract service provider of topical and transepithelial products supporting early-phase research, formulation development and in vitro testing services in addition to both clinical and commercial manufacturing. With MedPharm's recent merger with Tergus Pharma, MedPharm enhanced its capabilities, transforming the business into a truly differentiated CDMO of scale with superior end-to-end capabilities from drug development & formulation to large batch commercial manufacturing and distribution. For more than 25 years, MedPharm has specialized in reducing risk through its unique, industry-leading in vitro testing and research biology models and is a global leader in product development for dermal/transdermal, lung and nasal, mucosal membrane, ungual, otic, and ophthalmic delivery. MedPharm has locations in the United Kingdom and the United States, including a new 97,000 sq. ft. state-of-the-art manufacturing facility in Durham, NC. For more information, visit medpharm.com or follow us on LinkedIn.

About Ampersand Capital Partners
Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. For additional information, visit Ampersandcapital.com or follow on LinkedIn.

About Bourne Partners Strategic Capital ("BPSC")
Headquartered in Charlotte, N.C., Bourne Partners Strategic Capital is a private equity and growth equity investment firm focused exclusively on the pharmaceutical, pharma services and consumer healthcare sectors. As owners and operators with over 20 years of experience, BPSC has investment, strategic and operational experience in companies ranging from $5M to $3B in equity value and seeks to align and partner with management teams and other owners in these sectors to grow their businesses. BPSC is a related company of Bourne Partners, which offers investment banking and advisory services in the same key focus areas. For more information, Bourne Partners Strategic Capital.

About Great Point Partners
Great Point Partners, founded in 2003 and based in Greenwich, CT, manages over $1.9B of capital in its private funds and public life sciences equity strategy (BioMedical Value Fund). The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device contract manufacturing and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. For additional information, visit gppfunds.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/medpharm-appoints-bill-humphries-as-chief-executive-officer-to-lead-next-phase-of-strategic-growth-302366796.html

SOURCE MedPharm